There is no single “best” pain medication for psoriatic arthritis because the right choice depends on how active your disease is, which joints are affected, and whether you have other health conditions. That said, treatment guidelines are clear about a general hierarchy: anti-inflammatory painkillers for mild symptoms, disease-modifying drugs for moderate disease, and biologic injections for more severe or persistent joint inflammation. The key distinction with psoriatic arthritis is that simply managing pain isn’t enough. The disease causes progressive joint damage, so the most effective medications are the ones that target the underlying immune process driving that damage.
NSAIDs: The Usual Starting Point
For mild psoriatic arthritis with only a few tender or swollen joints, nonsteroidal anti-inflammatory drugs (like ibuprofen, naproxen, or celecoxib) are typically the first thing prescribed. They reduce both pain and inflammation quickly, often within hours, and are available over the counter or by prescription at higher doses. Clinical trials in psoriatic arthritis have used celecoxib at 200 to 400 mg daily and diclofenac at 75 to 150 mg daily, though your doctor will adjust based on your situation.
No single NSAID has proven more effective than another for psoriatic arthritis specifically, so the choice usually comes down to your individual risk profile. Celecoxib is gentler on the stomach than older NSAIDs like naproxen or diclofenac, but all NSAIDs carry risks for your kidneys and cardiovascular system with long-term use. Interestingly, one observational study of 200 psoriatic arthritis patients found that regular NSAID use was associated with lower cardiovascular risk, though this was seen only with traditional NSAIDs, not with celecoxib-type drugs.
The important thing to understand about NSAIDs is that they mask symptoms without slowing joint damage. They’re a bridge, not a long-term solution for most people. If your symptoms persist beyond a few weeks or you have more than mild disease, your treatment plan needs to go further.
Methotrexate and Other Oral Medications
When NSAIDs aren’t enough, the next step is usually an oral disease-modifying drug. Methotrexate is the most commonly used option. It works by dialing down the overactive immune response that causes joint inflammation and skin symptoms. The typical starting dose is 7.5 to 15 mg taken once a week (not daily), and doctors often increase it in 5 mg increments every couple of weeks up to a maximum of 25 mg per week. It can take 4 to 8 weeks before you notice improvement, so patience is part of the process.
Methotrexate is not an option if you have significant liver disease or chronic kidney disease, and it’s contraindicated during pregnancy. You’ll need regular blood tests to monitor your liver function while taking it. Other oral options in this category include leflunomide and sulfasalazine, which work through different mechanisms but serve a similar role.
Treatment guidelines note that doctors may consider NSAIDs before methotrexate in patients with less active disease, but for anyone with moderate symptoms or signs of joint damage on imaging, moving to a disease-modifying drug is the standard approach.
Biologic Injections: The Strongest Evidence
For people with active psoriatic arthritis, especially those with significant skin involvement or multiple swollen joints, biologics are the recommended first-line treatment. These are self-injected or infused medications that block specific immune signals responsible for inflammation.
TNF inhibitors (like adalimumab and etanercept) have the longest track record and are conditionally recommended over oral medications as first-line therapy by the American College of Rheumatology. They produce meaningful improvement in joint tenderness and swelling in roughly 50 to 60% of patients within the first few months.
IL-17 inhibitors (like secukinumab, ixekizumab, and the newer bimekizumab) perform similarly to TNF inhibitors for joint symptoms. In head-to-head trials, secukinumab matched adalimumab on arthritis outcomes, and ixekizumab showed numerically similar results. Where IL-17 inhibitors tend to shine is skin clearance, so if you have both significant joint disease and moderate-to-severe psoriasis, they may be a better fit. Bimekizumab, FDA-approved for psoriatic arthritis, blocks both IL-17A and IL-17F and achieved a 44% rate of significant joint improvement at 16 weeks compared to 10% with placebo.
The pooled data across classes tells a consistent story: TNF inhibitors and IL-17 inhibitors produce nearly identical joint response rates, with risk ratios of 2.23 and 2.30 respectively compared to placebo. Your choice between them often comes down to which other symptoms you’re dealing with and which health conditions you have.
Apremilast: An Oral Alternative to Biologics
Apremilast is an oral tablet that works by blocking a specific enzyme involved in inflammation. It sits between traditional oral drugs and biologics in terms of potency. In a meta-analysis, patients taking apremilast were about twice as likely as those on placebo to achieve at least a 20% improvement in joint counts, and nearly three times as likely to reach a 70% improvement threshold. It also produced meaningful gains in physical function scores.
Apremilast is a reasonable option if you prefer oral medication over injections, have milder disease, or can’t take biologics for medical reasons. It doesn’t require the routine blood monitoring that methotrexate does. The most common side effects are nausea and diarrhea, which typically improve after the first few weeks.
JAK Inhibitors: Newer Oral Options
JAK inhibitors are the newest class of oral medications approved for psoriatic arthritis. They block a group of immune signaling pathways inside cells and can produce improvements comparable to biologics. A network meta-analysis found that these drugs significantly improved both joint symptoms and skin clearance compared to placebo.
However, they come with more safety considerations than other options. Higher doses in particular carry an increased risk of serious side effects, including cardiovascular events, blood clots, and infections. The analysis found that different JAK inhibitors varied considerably in their safety profiles, with some carrying nearly twice the risk of adverse events compared to others. These medications are generally reserved for people who haven’t responded adequately to TNF inhibitors or other biologics.
Steroid Injections for Flares
When one or two joints are acutely inflamed during a flare, a corticosteroid injection directly into the joint can provide rapid relief, often within days. The typical dose is 20 to 40 mg of a steroid like triamcinolone, and these injections can be repeated with a minimum interval of 2 to 3 weeks between them, though most doctors prefer to space them at least 3 months apart. Doses of 80 mg or higher, or repeated injections into the same joint, carry a greater risk of cartilage thinning and other complications.
Steroid injections are a tool for managing acute episodes, not a substitute for ongoing treatment. If you’re needing frequent injections, it’s a sign your baseline therapy may need adjustment.
How Other Health Conditions Shape Your Options
Psoriatic arthritis rarely exists in isolation, and your other health conditions significantly narrow or expand your medication options. TNF inhibitors should be used with caution, or avoided entirely, if you have moderate-to-severe heart failure. In clinical studies, higher-dose infliximab actually increased the risk of hospitalization and death in patients with advanced heart failure. Etanercept, a different TNF inhibitor, appeared safer in that population, so the class isn’t uniformly off-limits.
If you have a neurological condition like multiple sclerosis or a history of demyelinating disease, TNF inhibitors are contraindicated because they’ve been linked to worsening of these conditions. IL-17 or IL-23 inhibitors are typically safer alternatives in this scenario.
Liver disease limits your use of methotrexate, leflunomide, and sulfasalazine. Chronic kidney disease restricts both NSAIDs and methotrexate. In either case, biologics become especially important because they’re processed differently and don’t put the same strain on these organs.
For anyone planning pregnancy, methotrexate and leflunomide are strictly off-limits due to the risk of birth defects. Certain TNF inhibitors have more established safety data in pregnancy, making them the preferred option during family planning.